abstract |
The invention comprises three adjacent segments N, L and C, represented by the formula NLC, comprising an N-helix region (N) of gp41, a C-helix region (C) of gp41 and between said N-helix and C-helix A variant polypeptide comprising a linking loop (L) comprising a synthetic linker located at the linker, wherein the linker is in a numbering scheme based on a prototype HIV-1 HxB2 Clade B separation strain Thus, amino acids 593 to 617 of gp41 are substituted and the polypeptide contains a 98.6 D epitope that neutralizes calveolin-1, but does not include 2F5 and 4E10 epitopes, fusion peptides, and the polypeptide Relates to a variant polypeptide, characterized in that it has minimal immune cross reactivity with human interleukin 2 (IL-2). |